Research programme: anti-TAG-72 monoclonal antibody - Quest PharmaTechAlternative Names: Anti-TAG-72 monoclonal antibody - Quest PharmaTech; AR54; MAb B72.3; Monoclonal antibody B72.3; OncoRex
Latest Information Update: 06 Mar 2014
At a glance
- Originator National Institutes of Health (USA)
- Developer Quest PharmaTech
- Class Cancer vaccines; Monoclonal antibodies
- Mechanism of Action Immunostimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer